<DOC>
	<DOCNO>NCT00450775</DOCNO>
	<brief_summary>The purpose study evaluate efficacy patient acceptance Dermatix Q prevention treatment scarring .</brief_summary>
	<brief_title>Evaluation Efficacy , Tolerability , Patient Acceptance Dermatix Q Prevention Management Scars</brief_title>
	<detailed_description />
	<criteria>Female male patient least 18 year age Patients serious risk hypertrophic scarring ( due family history , race , recent surgery , etc ) Able willing provide inform consent likely complete study visit All Fitzpatrick skin type evaluate Known contraindication Dermatix component Age scar &gt; 4 month Keloid scar ( scar increase fibroblastic activity exceed boundary original scar )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>